One Better Than the Other

Aceon Shown to Be More Effective in Offsetting Kidney Disease

| Sep 1, 2001

Australian researchers are saying the angiotensin-converting enzyme (ACE) inhibitor perindopril (Aceon) is more effective than the calcium channel blocker nifedipine (Procardia) in slowing the progression of kidney disease in people with diabetes who have normal blood pressure.

According to research published in the May issue of the American Journal of Kidney Diseases, George Jerums, MD, and colleagues from the University of Melbourne in Victoria, Australia, randomized 42 people to treatment with either Aceon, slow-release Procardia or placebo. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months.

After three years of treatment, average albumin excretion rates were 23 µg/min for the Aceon group, 122 µg/min for the Procardia group and 112 µg/min for the placebo group. In addition, only one Aceon-treated patient progressed to macroalbuminuria compared with four Procardia-treated and three placebo-treated patients. Also, seven Aceon-treated patients experienced a regression to normoalbuminuria compared with none of the other patients.

After Aceon treatment was discontinued, albumin excretion rates more than doubled during the first three months, while they remained about the same after discontinuing Procardia or placebo therapy.

Neither HbA1c nor cholesterol and triglyceride levels were changed.

The researchers concluded that long-term Aceon therapy is more effective than Procardia or placebo in delaying the progression of diabetic kidney disease and reducing albumin excretion rates to the normal range of 20 µg/min in type 1s with normal blood pressure and microalbuminuria.

Click Here To View Or Post Comments

Categories: A1c Test, Diabetes, Diabetes, Kidney Care (Nephropathy), Medications, Medications Research

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.